The First School of Clinical Medicine, Lanzhou University, 730030 Lanzhou, Gansu, China.
Institute of Modern Physics, Chinese Academy of Sciences, 730030 Lanzhou, Gansu, China.
Front Biosci (Landmark Ed). 2024 Apr 9;29(4):144. doi: 10.31083/j.fbl2904144.
Gliomas are characterized by aggressive behavior, leading to severe disability and high mortality. Ubiquitin-like modifier activating enzyme 2 (UBA2) is a subunit of the E1-activating enzyme involved in the SUMOylation (SUMO, small ubiquitin-related modifier) of numerous proteins. Although the abnormality of is linked to the progression of various tumor types, the role of in glioma is still unknown.
A bioinformatic analysis using several public databases was conducted to examine the expression level, clinicopathological correlations, and prognostic significance of UBA2 in glioma. The correlation between UBA2 expression and drug sensitivity in cancers was also explored. Multiple cellular experiments were conducted to validate the role of in glioma.
Analysis of multiple databases and cellular experiments revealed that UBA2 was overexpressed in glioma tissues and cell lines, respectively. UBA2 expression in gliomas correlated with World Health Organization (WHO) grade, gene status, deletion, histological type, and immune cell infiltration in glioma. UBA2 expression in carcinomas also correlated with drug sensitivity. Kaplan-Meier analysis revealed that high expression of UBA2 predicted poorer survival in glioma patients. A nomogram model containing UBA2 expression was constructed for clinical practice. Knockdown of was observed to suppress glioma cell progression and sensitize glioma cells to irradiation .
Overall, this research showed that might be involved not only in the development of glioma but also in the regulation of immunity, drug sensitivity, and radiosensitivity. Therefore, may be a potential target for therapy and a candidate biomarker for glioma diagnosis and prognosis.
神经胶质瘤的特点是侵袭性强，导致严重残疾和高死亡率。泛素样修饰酶激活酶 2（UBA2）是参与许多蛋白质 SUMO 化（SUMO，小泛素相关修饰物）的 E1 激活酶的亚基。尽管 的异常与多种肿瘤类型的进展有关，但 在神经胶质瘤中的作用尚不清楚。
使用多个公共数据库进行生物信息学分析，以检查 UBA2 在神经胶质瘤中的表达水平、临床病理相关性和预后意义。还探讨了 UBA2 表达与癌症药物敏感性的相关性。进行了多种细胞实验来验证 在神经胶质瘤中的作用。
对多个数据库和细胞实验的分析表明，UBA2 在神经胶质瘤组织和细胞系中分别过表达。UBA2 在神经胶质瘤中的表达与世界卫生组织（WHO）分级、 基因状态、 缺失、组织学类型和神经胶质瘤中的免疫细胞浸润相关。在癌中，UBA2 的表达也与药物敏感性相关。Kaplan-Meier 分析显示，UBA2 高表达预示着神经胶质瘤患者的生存预后较差。构建了包含 UBA2 表达的列线图模型用于临床实践。观察到敲低 可抑制神经胶质瘤细胞的进展并增加神经胶质瘤细胞对放疗的敏感性。
总的来说，这项研究表明， 可能不仅参与神经胶质瘤的发生，而且还参与免疫、药物敏感性和放射敏感性的调节。因此， 可能是治疗的潜在靶点，也是神经胶质瘤诊断和预后的候选生物标志物。
